Mitolytix Oncology Announces Preclinical Data Supporting the Therapeutic Potential of Molecule

EDMONTON, Alberta - April 7, 2021 - PRLog -- Building on studies on oxygen consumption rates, Mitolytix Research Ltd. commissioned the University to explore and characterize any morphological or growth changes that occur in response to The Catalyst (COI agent). Cells chosen for assays consisted of the H2172 human non-small cell carcinoma line and the MRC-9 human immortalized normal lung line. The university staff cultured small volumes of cells for 90-120 days treating every three days with nothing (Untreated), sterile water (Mock) or The Catalyst.

The study provided evidence that cellular reproduction is significantly slowed in response to The Catalyst compared to sterile water (Mock) treatment or untreated cultures grown in parallel, since there is no evident overwhelming increase in cellular death, yet the cultures hold lower volumes of cells as evidenced by reduced 3-dimensional growth in the Catalyst treated flasks and wells at later time points.

It is also clear that the normal cells (MRC-9) are impacted in a similar way by the Catalyst and Mock treatments in the university experiments compared to the cancer cells (H2172). Of note, The Catalyst treated H2172 cells appear at 40X magnification to have a slightly darker lipid layer which may impact cell-cell adhesion and migration of the malignant cells. This dark lipid layer is less noticeable in the MRC-9 cells treated with the Catalyst.

https://mitolytix.com/